Multitarget-based cotreatment with cilostazol and celecoxib synergistically suppresses collagen-induced arthritis in mice by enhancing interleukin-10 expression.

In conclusion, serum IL-10 levels in these mice were markedly increased by cilostazol and celecoxib cotreatment, whereas elevated serum IL-1β levels were markedly reduced. Cotreatment with low-dose cilostazol and celecoxib may ensure the synergistic anti-arthritic potential. PMID: 31170675 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31170675?dopt=Abstract

Source: International Immunopharmacology - June 2, 2019 Category: Allergy & Immunology Authors: Park SY, Lee YS, Lee SY, Lee SW, Hong KW, Kim CD Tags: Int Immunopharmacol Source Type: research